{"id":2988,"date":"2026-09-01T09:42:40","date_gmt":"2026-09-01T09:42:40","guid":{"rendered":"https:\/\/pevropeptides.com\/?post_type=product&#038;p=2988"},"modified":"2026-09-02T12:14:33","modified_gmt":"2026-09-02T12:14:33","slug":"igf-1-lr3-1mg","status":"publish","type":"product","link":"https:\/\/pevropeptides.com\/sk\/product\/igf-1-lr3-1mg\/","title":{"rendered":"IGF-1 LR3 1 mg"},"content":{"rendered":"<p><strong>Len na laborat\u00f3rne a v\u00fdskumn\u00e9 \u00fa\u010dely. Nie je ur\u010den\u00e9 na hum\u00e1nne ani veterin\u00e1rne pou\u017eitie.<\/strong><\/p>\n<p>IGF-1 LR3 je rekombinantne vyroben\u00fd prote\u00ednov\u00fd anal\u00f3g s modifikovanou \u0161trukt\u00farou re\u0165azca, ktor\u00fd sa \u0161tuduje v kontrolovan\u00fdch laborat\u00f3rnych prostrediach v kontexte peptidmi sprostredkovan\u00fdch sign\u00e1lnych dr\u00e1h a molekul\u00e1rnych regula\u010dn\u00fdch syst\u00e9mov. Vo vedeckom v\u00fdskume sa t\u00e1to zl\u00fa\u010denina pou\u017e\u00edva ako modelov\u00e1 zl\u00fa\u010denina a ako referen\u010dn\u00fd \u0161tandard pri analytick\u00fdch pr\u00e1cach s dlh\u0161\u00edmi polypeptidov\u00fdmi re\u0165azcami. T\u00e1to zl\u00fa\u010denina sa pon\u00faka ako lyofiliz\u00e1t su\u0161en\u00fd mrazom v uzavretej 1 mg v\u00fdskumnej liekovke.<\/p>\n<h2>\u010co je IGF-1 LR3?<\/h2>\n<p>IGF-1 LR3 je jednoduch\u00fd, neglykozylovan\u00fd polypeptidov\u00fd re\u0165azec s 83 aminokyselinami, \u0161truktur\u00e1lne odvoden\u00fd od inzul\u00ednu podobn\u00e9ho rastov\u00e9ho faktora 1 (IGF-1). Re\u0165azec sa od neho l\u00ed\u0161i v dvoch definovan\u00fdch bodoch: v polohe 3 je namiesto zvy\u0161ku kyseliny glut\u00e1movej pr\u00edtomn\u00fd argin\u00ednov\u00fd zvy\u0161ok a na N-koniec bolo pridan\u00e9 pred\u013a\u017eenie trin\u00e1stich aminokysel\u00edn. Obe modifik\u00e1cie menia rozlo\u017eenie n\u00e1boja a priestorov\u00fa \u0161trukt\u00faru N-termin\u00e1lnej dom\u00e9ny; jadro stabilizovan\u00e9 tromi disulfidov\u00fdmi most\u00edkmi zost\u00e1va neporu\u0161en\u00e9.<\/p>\n<p>Vo v\u00fdskumn\u00fdch modeloch sa IGF-1 LR3 sk\u00fama v s\u00favislosti s modelovan\u00edm interakci\u00ed receptorov a prenosom sign\u00e1lu v bunkov\u00fdch modeloch. Cie\u013eom op\u00edsan\u00fdm v literat\u00fare je receptor IGF-1 (IGF1R); okrem toho sa opisuje v\u00fdznamne zn\u00ed\u017een\u00e1 afinita k v\u00e4zbov\u00fdm prote\u00ednom (IGFBP) spojen\u00e1 so zmenenou N-termin\u00e1lnou \u0161trukt\u00farou. V d\u00f4sledku toho sa IGF-1 LR3 pou\u017e\u00edva ako modelov\u00e1 zl\u00fa\u010denina a referen\u010dn\u00e1 l\u00e1tka vo vedeckom v\u00fdskume.<\/p>\n<h2>Oblasti v\u00fdskumu<\/h2>\n<p>V laborat\u00f3rnom kontexte sa IGF-1 LR3 vyskytuje okrem in\u00e9ho v nasleduj\u00facich oblastiach v\u00fdskumu:<\/p>\n<ul>\n<li>Modelovanie interakci\u00ed receptorov a v\u00fdskum v\u00e4zbovej geometrie prote\u00ednov\u00fdch anal\u00f3gov na op\u00edsan\u00fa receptorov\u00fa dom\u00e9nu.<\/li>\n<li>\u0160t\u00fadie peptidmi sprostredkovan\u00fdch sign\u00e1lnych dr\u00e1h a molekul\u00e1rnych regula\u010dn\u00fdch siet\u00ed v kontrolovan\u00fdch bunkov\u00fdch modeloch in vitro.<\/li>\n<li>\u0160t\u00fadia vz\u0165ahu medzi \u0161trukt\u00farou a aktivitou zameran\u00e1 na pr\u00edspevok jednotliv\u00fdch aminokyselinov\u00fdch substit\u00faci\u00ed k v\u00e4zbov\u00e9mu spr\u00e1vaniu.<\/li>\n<li>V\u00fdskum interakci\u00ed prote\u00edn-prote\u00edn, najm\u00e4 afinity anal\u00f3gov k v\u00e4zbe nosn\u00fdch prote\u00ednov.<\/li>\n<li>\u0160t\u00fadie konform\u00e1cie a stability dlh\u0161\u00edch polypeptidov\u00fdch re\u0165azcov: skladanie, integrita disulfidov a profily proteolytickej degrad\u00e1cie in vitro.<\/li>\n<li>V\u00fdvoj a valid\u00e1cia analytick\u00fdch met\u00f3d (HPLC, LC-MS, SDS-PAGE) s pou\u017eit\u00edm IGF-1 LR3 ako referen\u010dn\u00e9ho \u0161tandardu.<\/li>\n<\/ul>\n<p>Ka\u017ed\u00e1 z t\u00fdchto aplik\u00e1ci\u00ed zah\u0155\u0148a kontrolovan\u00fd laborat\u00f3rny alebo predklinick\u00fd modelov\u00fd v\u00fdskum.<\/p>\n<h2>Analytick\u00e1 \u0161pecifik\u00e1cia<\/h2>\n<p>Materi\u00e1l sa predklad\u00e1 s kontrolovanou \u010distotou \u2265 99 %, stanovenou pomocou vysokotlakovej kvapalinovej chromatografie (HPLC). Pre prote\u00edny s touto d\u013a\u017ekou re\u0165azca je rozhoduj\u00faca identita a \u010distota: okrem klasick\u00fdch ne\u010dist\u00f4t sa m\u00f4\u017eu vyskytn\u00fa\u0165 aj s\u00favisiace varianty \u2013 skr\u00e1ten\u00e9 re\u0165azce, nespr\u00e1vne zlo\u017een\u00e9 formy alebo oxidovan\u00e9 zvy\u0161ky \u2013 ktor\u00e9 s\u00fa svojou hmotnos\u0165ou bl\u00edzke cie\u013eovej molekule a priamo ovplyv\u0148uj\u00fa interpret\u00e1ciu meran\u00ed v\u00e4zby a \u0161trukt\u00fary. Preh\u013ead dostupnej analytickej dokument\u00e1cie n\u00e1jdete na na\u0161ej <a href=\"https:\/\/lumopeptides.com\/labresultaten\/\" target=\"_blank\" rel=\"noopener\">str\u00e1nka s v\u00fdsledkami laborat\u00f3rnych testov<\/a>.<\/p>\n<h2>\u0160pecifik\u00e1cie<\/h2>\n<table>\n<thead>\n<tr>\n<th>\u0160pecifik\u00e1cia<\/th>\n<th>Hodnota<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Vzorka<\/td>\n<td>IGF-1 LR3<\/td>\n<\/tr>\n<tr>\n<td>Synonym\u00e1<\/td>\n<td>P\u013e\u00facny R3-IGF-1; P\u013e\u00facny argin\u00edn 3-IGF-1; LR3-IGF-1<\/td>\n<\/tr>\n<tr>\n<td>\u0160trukt\u00fara dod\u00e1vate\u013esk\u00e9ho re\u0165azca<\/td>\n<td>83 aminokysel\u00edn; argin\u00edn namiesto kyseliny glut\u00e1movej v poz\u00edcii 3; N-termin\u00e1lne pred\u013a\u017eenie 13 aminokysel\u00edn<\/td>\n<\/tr>\n<tr>\n<td>\u010c\u00edslo CAS<\/td>\n<td>143045-27-6 (tie\u017e registrovan\u00fd ako 946870-92-4)<\/td>\n<\/tr>\n<tr>\n<td>Molekulov\u00e1 hmotnos\u0165<\/td>\n<td>\u00b1 9 117,6 Da<\/td>\n<\/tr>\n<tr>\n<td>Trieda<\/td>\n<td>Rekombinantne produkovan\u00fd prote\u00ednov\u00fd anal\u00f3g; jednoduch\u00fd, neglykozylovan\u00fd polypeptidov\u00fd re\u0165azec<\/td>\n<\/tr>\n<tr>\n<td>Formul\u00e1r<\/td>\n<td>Lyofiliz\u00e1t su\u0161en\u00fd mrazom v uzavretej liekovke<\/td>\n<\/tr>\n<tr>\n<td>Mno\u017estvo na injek\u010dn\u00fa liekovku<\/td>\n<td>1 mg<\/td>\n<\/tr>\n<tr>\n<td>\u010cistota<\/td>\n<td>\u2265 99 % (HPLC)<\/td>\n<\/tr>\n<tr>\n<td>Skladovanie<\/td>\n<td>Skladujte na chladnom a tmavom mieste, chr\u00e1nen\u00e9 pred svetlom a vlhkos\u0165ou.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Tvar, manipul\u00e1cia a skladovanie<\/h2>\n<p>IGF-1 LR3 sa dod\u00e1va ako lyofiliz\u00e1t su\u0161en\u00fd mrazen\u00edm v uzavretej liekovke obsahuj\u00facej 1 mg materi\u00e1lu. M\u00e1 formu bieleho a\u017e takmer bieleho pr\u00e1\u0161ku alebo kompaktn\u00e9ho kol\u00e1\u010da; oboje je norm\u00e1lnym v\u00fdsledkom procesu lyofiliz\u00e1cie. Tento proces zachov\u00e1va molekul\u00e1rnu integritu polypeptidov\u00e9ho re\u0165azca po\u010das skladovania a prepravy. Rekon\u0161tit\u00facia sa vykon\u00e1va pod\u013ea protokolu laborat\u00f3ria, ktor\u00e9 ju vykon\u00e1va.<\/p>\n<p>Utesnen\u00fd lyofiliz\u00e1t skladujte na chladnom, suchom a tmavom mieste v p\u00f4vodnom obale; pre dlhodob\u00e9 skladovanie plat\u00ed teplota mrazenia. Obmedzte po\u010det cyklov mrazenia a rozmrazovania, ktor\u00e9 m\u00f4\u017eu ohrozi\u0165 integritu dlh\u0161\u00edch re\u0165azcov. Dodr\u017eiavajte \u0161tandardn\u00e9 laborat\u00f3rne opatrenia: \u010dist\u00e9 pracovn\u00e9 prostredie, vhodn\u00e9 ochrann\u00e9 prostriedky, \u017eiadna kr\u00ed\u017eov\u00e1 kontamin\u00e1cia a mimo dosahu neopr\u00e1vnen\u00fdch os\u00f4b. Zvy\u0161n\u00fd materi\u00e1l zlikvidujte v s\u00falade s platn\u00fdmi laborat\u00f3rnymi pokynmi.<\/p>\n<h2>IGF-1 LR3 v na\u0161om v\u00fdskumnom sortimente<\/h2>\n<p>IGF-1 LR3 patr\u00ed do kateg\u00f3rie lyofilizovan\u00fdch sk\u00faman\u00fdch zl\u00fa\u010den\u00edn vo forme liekoviek v r\u00e1mci n\u00e1\u0161ho sortimentu. V\u00fdskumn\u00edci v tejto kateg\u00f3rii \u010dasto kombinuj\u00fa t\u00fato zl\u00fa\u010deninu s materi\u00e1lmi, ktor\u00e9 sa \u0161tuduj\u00fa prostredn\u00edctvom ich vlastn\u00e9ho molekul\u00e1rneho cie\u013ea. Zatia\u013e \u010do IGF-1 LR3 sa vyzna\u010duje d\u013a\u017ekou re\u0165azca a definovan\u00fdm cie\u013eom viazan\u00fdm na receptor, in\u00e9 zlo\u017eky tej istej produktovej rady boli vybran\u00e9 tak, aby pokr\u00fdvali krat\u0161ie sekvencie, koordin\u00e1ciu viazan\u00fa na kov alebo enzymatick\u00e9 ciele. Tieto materi\u00e1ly maj\u00fa rovnak\u00fa lyofilizovan\u00fa formu liekovky, ale l\u00ed\u0161ia sa molekul\u00e1rnou triedou a sk\u00faman\u00fdm mechanizmom.<\/p>\n<h2>\u010casto kladen\u00e9 ot\u00e1zky<\/h2>\n<p><strong>Do ktorej triedy l\u00e1tok patr\u00ed IGF-1 LR3?<\/strong><br \/>Rekombinantne vyroben\u00fd prote\u00ednov\u00fd anal\u00f3g: jeden neglykozylovan\u00fd polypeptidov\u00fd re\u0165azec s 83 aminokyselinami, patriaci k modifikovan\u00fdm anal\u00f3gom inzul\u00ednu podobn\u00e9ho rastov\u00e9ho faktora 1.<\/p>\n<p><strong>Pre\u010do s\u00fa \u0161truktur\u00e1lne modifik\u00e1cie relevantn\u00e9 vo v\u00fdskume?<\/strong><br \/>Re\u0165azec sa od z\u00e1kladnej \u0161trukt\u00fary odchy\u013euje presne v dvoch bodoch: jedna substit\u00facia v polohe 3 a N-termin\u00e1lne pred\u013a\u017eenie. V\u010faka tomu je u\u017eito\u010dn\u00fd na modelovanie pr\u00edspevku jednotliv\u00fdch \u0161truktur\u00e1lnych prvkov k v\u00e4zbov\u00e9mu spr\u00e1vaniu.<\/p>\n<p><strong>V akej forme je dod\u00e1van\u00e9 pripojenie?<\/strong><br \/>Ako lyofiliz\u00e1t su\u0161en\u00fd mrazom v uzavretej liekovke obsahuj\u00facej 1 mg materi\u00e1lu s \u010distotou \u2265 99 % (HPLC).<\/p>\n<p><strong>Ak\u00fa farbu a text\u00faru m\u00e1 materi\u00e1l?<\/strong><br \/>Biely a\u017e sivobiely pr\u00e1\u0161ok alebo kompaktn\u00fd kol\u00e1\u010d. Obe s\u00fa norm\u00e1lne a neznamenaj\u00fa kvalitu ani chybu.<\/p>\n<p><strong>Ako m\u00e1m materi\u00e1l skladova\u0165?<\/strong><br \/>Skladujte na chladnom, suchom a tmavom mieste v p\u00f4vodnom obale. Pre dlhodob\u00e9 skladovanie uchov\u00e1vajte pri teplote mrazu; obmedzte po\u010det cyklov zmrazovania a rozmrazovania.<\/p>","protected":false},"excerpt":{"rendered":"<p><strong>IGF-1 LR3<\/strong> je syntetick\u00fd prote\u00edn s modifikovanou \u0161trukt\u00farou v porovnan\u00ed s prirodzen\u00fdm variantom. V analytickom a biochemickom v\u00fdskume sa IGF-1 LR3 pou\u017e\u00edva ako referen\u010dn\u00fd \u0161tandard pre anal\u00fdzy dlh\u0161\u00edch peptidov a stability prote\u00ednov.<\/p>","protected":false},"featured_media":3231,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[124,121],"product_tag":[],"class_list":["post-2988","product","type-product","status-publish","has-post-thumbnail","product_cat-musculoskeletaal-onderzoek","product_cat-peptides","first","instock","shipping-taxable","purchasable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/pevropeptides.com\/sk\/wp-json\/wp\/v2\/product\/2988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pevropeptides.com\/sk\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/pevropeptides.com\/sk\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/pevropeptides.com\/sk\/wp-json\/wp\/v2\/comments?post=2988"}],"version-history":[{"count":1,"href":"https:\/\/pevropeptides.com\/sk\/wp-json\/wp\/v2\/product\/2988\/revisions"}],"predecessor-version":[{"id":3050,"href":"https:\/\/pevropeptides.com\/sk\/wp-json\/wp\/v2\/product\/2988\/revisions\/3050"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pevropeptides.com\/sk\/wp-json\/wp\/v2\/media\/3231"}],"wp:attachment":[{"href":"https:\/\/pevropeptides.com\/sk\/wp-json\/wp\/v2\/media?parent=2988"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/pevropeptides.com\/sk\/wp-json\/wp\/v2\/product_brand?post=2988"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/pevropeptides.com\/sk\/wp-json\/wp\/v2\/product_cat?post=2988"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/pevropeptides.com\/sk\/wp-json\/wp\/v2\/product_tag?post=2988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}